Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Jun 6;2013(6):CD003086.
doi: 10.1002/14651858.CD003086.pub3.

Opioid antagonists for smoking cessation

Sean P David  1 , Tim Lancaster, Lindsay F Stead, A Eden Evins, Judith J Prochaska
Affiliations
Meta-Analysis

Opioid antagonists for smoking cessation

Sean P David et al. Cochrane Database Syst Rev. .

Abstract

Background: The reinforcing properties of nicotine may be mediated through release of various neurotransmitters both centrally and systemically. People who smoke report positive effects such as pleasure, arousal, and relaxation as well as relief of negative affect, tension, and anxiety. Opioid (narcotic) antagonists are of particular interest to investigators as potential agents to attenuate the rewarding effects of cigarette smoking.

Objectives: To evaluate the efficacy of opioid antagonists in promoting long-term smoking cessation. The drugs include naloxone and the longer-acting opioid antagonist naltrexone.

Search methods: We searched the Cochrane Tobacco Addiction Group Specialised Register for trials of naloxone, naltrexone and other opioid antagonists and conducted an additional search of MEDLINE using 'Narcotic antagonists' and smoking terms in April 2013. We also contacted investigators, when possible, for information on unpublished studies.

Selection criteria: We considered randomised controlled trials comparing opioid antagonists to placebo or an alternative therapeutic control for smoking cessation. We included in the meta-analysis only those trials which reported data on abstinence for a minimum of six months. We also reviewed, for descriptive purposes, results from short-term laboratory-based studies of opioid antagonists designed to evaluate psycho-biological mediating variables associated with nicotine dependence.

Data collection and analysis: We extracted data in duplicate on the study population, the nature of the drug therapy, the outcome measures, method of randomisation, and completeness of follow-up. The main outcome measure was abstinence from smoking after at least six months follow-up in patients smoking at baseline. Abstinence at end of treatment was a secondary outcome. We extracted cotinine- or carbon monoxide-verified abstinence where available. Where appropriate, we performed meta-analysis, pooling risk ratios using a Mantel-Haenszel fixed-effect model.

Main results: Eight trials of naltrexone met inclusion criteria for meta-analysis of long-term cessation. One trial used a factorial design so five trials compared naltrexone versus placebo and four trials compared naltrexone plus nicotine replacement therapy (NRT) versus placebo plus NRT. Results from 250 participants in one long-term trial remain unpublished. No significant difference was detected between naltrexone and placebo (risk ratio (RR) 1.00; 95% confidence interval (CI) 0.66 to 1.51, 445 participants), or between naltrexone and placebo as an adjunct to NRT (RR 0.95; 95% CI 0.70 to 1.30, 768 participants). The estimate was similar when all eight trials were pooled (RR 0.97; 95% CI 0.76 to 1.24, 1213 participants). In a secondary analysis of abstinence at end of treatment, there was also no evidence of any early treatment effect, (RR 1.03; 95% CI 0.88 to 1.22, 1213 participants). No trials of naloxone or buprenorphine reported abstinence outcomes.

Authors' conclusions: Based on data from eight trials and over 1200 individuals, there was no evidence of an effect of naltrexone alone or as an adjunct to NRT on long-term smoking abstinence, with a point estimate strongly suggesting no effect and confidence intervals that make a clinically important effect of treatment unlikely. Although further trials might narrow the confidence intervals they are unlikely to be a good use of resources.

PubMed Disclaimer

Conflict of interest statement

Nil.

Figures

1
1
Naltrexone versus placebo (single pharmacotherapy or adjunct to NRT), Abstinence at longest follow up.
1.1
1.1. Analysis
Comparison 1 Naltrexone versus placebo (single pharmacotherapy or adjunct to NRT), Outcome 1 Abstinence at longest follow‐up.
1.2
1.2. Analysis
Comparison 1 Naltrexone versus placebo (single pharmacotherapy or adjunct to NRT), Outcome 2 Abstinence at end of treatment.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

°Boureau 1978 {published data only}
    1. Boureau F, Willer JC. Failure of naloxone to modify the anti‐tobacco effect of acupuncture [Desintoxication tabagique par l'acupuncture: essai negatif de blocage par la naloxone]. Nouvelle Presse Médicale 1978;7(16):1401. - PubMed
°Brauer 1999 {published data only}
    1. Brauer LH, Behm FM, Westman EC, Patel P, Rose JE. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology Berl 1999;143:339‐46. - PubMed
°Caskey 2001 {published data only}
    1. Caskey NH, Olmstead RE, Jarvik ME, Madsen DC, Iwamoto‐Schaap PN, Terrace S, et al. The acute effects of low dose naltrexone on ad lib smoking in normal heavy smokers (PO2 77). Society for Research on Nicotine and Tobacco 7th Annual Meeting March 23‐23 Seattle Washington. 2001:Abstracts book p106.
°Epstein 2004 {published data only}
    1. Epstein AM, King AC. Naltrexone attenuates behavioral and objective measures of cigarette smoking (POS1‐29). Society for Research on Nicotine and Tobacco 9th Annual Meeting February 19‐22 New Orleans, Louisiana. 2003:Abstracts book p43.
    1. Epstein AM, .King AC. Naltrexone attenuates acute cigarette smoking behavior. Pharmacology, Biochemistry & Behavior 2004;77:29‐37. - PubMed
°Gorelick 1988 {published data only}
    1. Gorelick DA, Rose JE, Jarvik ME. Effect of naloxone on cigarette smoking. Journal of Substance Abuse 1988;1:153‐9. - PubMed
°Houtsmuller 1997 {published data only}
    1. Houtsmuller EJ, Clemmey PA, Sigler LA, Stitzer ML. Effects of naltrexone on smoking and abstinence (In: Problems of Drug Dependence 1996, Proceedings of the 58th annual Conference). Nida Research Monograph 1997;174:68. - PubMed
°Hutchison 1999 {published data only}
    1. Hutchison KE, Monti PM, Rohsenow DJ, Swift RM, Colby SM, Gnys M, et al. Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology Berl 1999;142:139‐43. - PubMed
°Karras 1980 {published data only}
    1. Karras A, Kane JM. Naloxone reduces cigarette smoking. Life Sciences 1980;27:1541‐5. - PubMed
°King 2000 {published data only}
    1. King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine‐dependent subjects. Pharmacology, Biochemistry & Behavior 2000;66(3):563‐72. - PubMed
°Knott 2007 {published data only}
    1. Knott VJ, Fisher DJ. Naltrexone alteration of the nicotine‐induced EEG and mood activation in tobacco‐deprived cigarette smokers. Experimental and Clinical Psychopharmacology 2007;15(4):368‐81. - PubMed
°Krishnan‐Sarin 1999 {published data only}
    1. Krishnan‐Sarin S, Rosen MI, O'Malley SS. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Archives of General Psychiatry 1999;56(7):663‐8. - PubMed
°Lee 2005 {published data only}
    1. Lee YS, Joe KH, Sohn IK, Na C, Kee BS, Chae SL. Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment. Progress in Neuro‐psychopharmacol and Biological Psychiatry 2005;29(5):639‐47. - PubMed
    1. Na C, Ku YS, Lee YS. Smoking behavior and hormonal change after naltrexone in nicotine dependence. 156th Annual Meeting of the American Psychiatric Association, May 17 22, San Francisco CA. 2003:NR694.
°Mello 1985 {published data only}
    1. Mello NK, Lukas SE, Mendelson JH. Buprenorphine effects on cigarette smoking. Psychopharmacology Berl 1985;86(4):417‐25. [PUBMED: PMID 3929312] - PubMed
°Mutschler 2002 {published data only}
    1. Mutschler NH, Stephen BJ, Teoh SK, Mendelson JH, Mello NK. An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids. Nicotine & Tobacco Research 2002;4(2):223‐8. - PubMed
°Nemeth‐Coslett 1986 {published data only}
    1. Nemeth‐Coslett R, Griffiths RR. Naloxone does not affect cigarette smoking. Psychopharmacology Berl 1986;89(3):261‐4. - PubMed
°O'Malley 1998 {published data only}
    1. O'Malley S, Krishnan‐Sarin SS, Meandzija B. Naltrexone in the treatment of nicotine dependence: A preliminary study. Proceedings of the American Psychiatric Association Annual Meeting. 1997.
    1. O'Malley SS, Krishnan‐Sarin S, Meandzija B. Naltrexone treatment of nicotine dependence: a preliminary study. Addiction 1998;93(6):918‐9.
°Olmstead 2002 {published data only}
    1. Olmstead RE, Caskey NH, Madsen DC, Terrace S, Iwamoto‐Schaap PN, Griffith TM, et al. The acute effects of low dose naltrexone on ad lib smoking in normal heavy smokers and chippers. Proceedings for the Society of Research on Nicotine and Tobacco 8th Annual Meeting, Savannah GA. 2002.
°Ray 2006 {published data only}
    1. Ray R, Jepson C, Patterson F, Strasser A, Rukstalis M, Perkins K, Lynch KG, O'Malley S, Berrettini WH, Lerman C. Association of OPRM1 A11G variant with the relative reinforcing value of nicotine. Psychopharmacology Berl 2006;188(3):355‐363. - PubMed
°Ray 2007 {published data only}
    1. Ray RA, Miranda R, Kahler CW, Leventhal AM, Monti PM, Swift R, et al. Pharmacological effects of naltrexone and intervenous alcohol on craving for cigarettes among light smokers: a pilot study. Psychopharmacology Berl 2007;193(4):449‐56. - PubMed
°Rohsenow 2003 {published data only}
    1. Rohsenow DJ, Monti PM, Colby SM, Gulliver SB, Swift RM, Abrams DB. Naltrexone treatment for alcoholics: effect on cigarette smoking rates. Nicotine & Tobacco Research 2003;5(2):231‐6. - PubMed
°Rohsenow 2007 {published data only}
    1. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD, et al. High‐dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Experimental and Clinical Psychopharmacology 2007;15(1):81‐92. - PubMed
°Rukstalis 2005 {published data only}
    1. Rukstalis M, Jepson C, Strasser A, Lynch KG, Perkins K, Patterson F, et al. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology Berl 2005;180:41‐8. - PubMed
°Sutherland 1995 {published data only}
    1. Sutherland G, Stapleton JA, Russell MA, Feyerabend C. Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology Berl 1995;120(4):418‐25. - PubMed
°Wewers 1998 {published data only}
    1. Wewers ME, Dhatt R, Tejwani GA. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology Berl 1998;140(2):185‐90. - PubMed
    1. Wewers ME, Dhatt RK, Tejwani GA. Naltrexone administration influences cigarette smoking behaviour. Nicotine & Tobacco Research 1999;1(1):112‐3.
Baltieri 2009 {published and unpublished data}
    1. Baltieri DA, Daró FR, Ribeiro PL, Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008;103(12):2035‐44. - PubMed
    1. Baltieri DA, Daró FR, Ribeiro PL, Andrade AG. Effects of topiramate or naltrexone on tobacco use among male alcohol‐dependent outpatients. Drug and Alcohol Dependence 2009;105(1‐2):33‐41. - PubMed
Covey 1999 {published data only}
    1. Covey LS, Glassman AH, Stetner F. Naltrexone effects on short‐term and long‐term smoking cessation. Journal of Addictive Diseases 1999;18:31‐40. - PubMed
    1. Covey LS, Glassman AH, Stetner F. Naltrexone for smoking cessation. Journal of Addictive Diseases 1996;15:147. - PubMed
King 2006 {published data only}
    1. King A, Chilton E, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: effects of gender on clinical response (PA8‐6). Society for Research on Nicotine and Tobacco 9th Annual Meeting February 19‐22 New Orleans, Louisiana. 2003:32.
    1. King A, Wit H, Riley RC, Cao D, Niaura R, Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine & Tobacco Research 2006;8:671‐82. - PubMed
    1. King AC, Chilton E, Niaura R. Role of naltrexone in initial smoking cessation: preliminary findings. Alcoholism, Clinical and Experimental Research 2002;26(12):1942‐4. - PubMed
King 2012 {published data only}
    1. Fucito LM, Toll BA, Roos CR, King AC. Medication expectancies predict smoking cessation success. Society for Research on Nicotine and Tobacco 19th Annual Meeting March 13‐16 Boston MA. 2013:58.
    1. King AC, Cao D, O'Malley SS, Kranzler HR, Cai X, Dewit H, et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine‐dependent men and women. Journal of Clinical Psychopharmacology 2012;32(5):630‐6. [] - PMC - PubMed
    1. King AC, Cao D, Zhang L, O'Malley SS. Naltrexone reduction of long‐term smoking cessation weight gain in women but not men: A randomized controlled trial. Biological Psychiatry 2013;73(9):924‐30. [] - PMC - PubMed
    1. King AC, Zhang L, Cao D. Heavy drinkers show more pronounced effects of naltrexone on drinking and smoking outcomes within smoking cessation treatment. Alcoholism, Clinical and Experimental Research: 35th Annual Scientific Meeting of the Research Society on Alcoholism 2012; Vol. 36:366A. []
Meszaros 2010 {published and unpublished data}
    1. Szombathyne‐Meszaros Z, Dimmock JA, Ploutz‐Snyder R, Batki SL. Oral naltrexone treatment for alcohol dependence in schizophrenia is not effective for smoking cessation. Alcoholism, Clinical and Experimental Research 2010;34(S2):176A. [CRS: 9400123000016479; DOI: 10.1111/acer.2010.34.issue-s2/issuetoc] - DOI
O'Malley 2006 {published and unpublished data}
    1. Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, et al. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug and Alcohol Dependence 2010;112(1‐2):1‐8. [] - PMC - PubMed
    1. King AC, Cao D, Zhang L, O'Malley SS. Naltrexone reduction of long‐term smoking cessation weight gain in women but not men: A randomized controlled trial. Biological Psychiatry 2012:epub Nov 21. [] - PMC - PubMed
    1. O'Malley SS, Cooney JL, Krishna‐Sarin S, Dubin JA, McKee SA, Cooney NL, et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of Internal Medicine 2006;166(6):667‐74. - PubMed
    1. O'Malley SS, Krishnan‐Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, et al. Dose‐dependent reduction of hazardous alcohol use in a placebo‐controlled trial of naltrexone for smoking cessation. International Journal of Neuropsychopharmacology 2009;12(5):589‐97. [] - PMC - PubMed
    1. Peters EN, Fucito LM, Novosad C, Toll BA, O'Malley SS. Effect of night smoking, sleep disturbance, and their co‐occurrence on smoking outcomes. Psychology of Addictive Behaviors 2011;25(2):312‐9. [] - PMC - PubMed
Toll 2010a {published and unpublished data}
    1. O'Malley SS. Testing the effectiveness of low dose naltrexone for smoking cessation and minimization of post‐cessation weight gain. http://clinicaltrials.gov/show/NCT00105482 (accessed 22nd May 2013) 2005. []
    1. Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, et al. Low‐dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: A randomized trial. Drug and Alcohol Dependence 2010; Vol. 111, issue 3:200‐6. [] - PMC - PubMed
Wong 1999 {published data only}
    1. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction 1999;94(8):1227‐37. - PubMed

References to studies excluded from this review

Ahmadi 2003 {published data only}
    1. Ahmadi J, Ashkani H, Ahmadi M, Ahmadi N. Twenty‐four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. Journal of Substance Abuse and Treatment 2003;24:251‐5. - PubMed
Byars 2005 {published data only}
    1. Byars JA, Frost‐Pineda K, Jacobs WS, Gold MS. Naltrexone augments the effects of nicotine replacement therapy in female smokers. Journal of Addictive Diseases 2005;24:49‐60. - PubMed
Croop 2000 {published data only (unpublished sought but not used)}
    1. Croop R. Correspondence with Dr. Robert Croop of the DuPont Merck Pharmaceutical Company. 7 July 2000. Personal communication.
Krishnan‐Sarin 2003 {published data only}
    1. Krishnan‐Sarin S, Meandzija B, O'Malley S. Naltrexone and nicotine patch in smoking cessation: a preliminary study. Nicotine & Tobacco Research 2003;5(6):851‐7. - PubMed
O'Malley 1995 {published data only}
    1. O'Malley SS, Croop RS, Wroblewski JW, Labriola DF, Volpicelli JR. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatric Annals 1995;25:681‐8.
Roozen 2006 {published data only}
    1. Roozen HG, Beers SE, Weevers HJ, Breteler MH, Willemsen MC, Postmus PE, et al. Effects on smoking cessation: naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach. Substance Use and Misuse 2006;41(2):45‐60. - PubMed
Toll 2008 {published data only}
    1. Toll BA. Low‐dose naltrexone combined with bupropion to stop smoking with less weight gain. Http://clinicaltrials.gov/show/NCT00129246 2004. []
    1. Toll BA, Leary V, We R, Salovey P, Meandzija B, O'Malley SS. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addictive Behaviors 2008;33(1):173‐179. - PMC - PubMed
Toll 2010b {published data only}
    1. Toll BA, Wu R, Meandzija B, O’Malley S. Naltrexone and varenicline: weight gain and tolerability in smokers [POS2‐18]. Society for Research on Nicotine and Tobacco 16th Annual Meeting February 24‐27 Baltimore, MD. 2010.
Wilcox 2010 {published data only}
    1. Wilcox CS, Oskooilar N, Erickson JS, Billes SK, Katz BB, Tollefson G, et al. An open‐label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addictive Behaviors 2010;35(3):229‐34. [PUBMED: 19926400] - PubMed

References to ongoing studies

Ray 2012 {published data only}
    1. Courtney KE, Ray LA. Singular and combined effects of varenicline and naltrexone for the treatment of heavy drinking smokers. Society for Research on Nicotine and Tobacco 19th Annual Meeting March 13‐16 Boston MA. 2013.
    1. Ray LA, Courtney KE, London ED, Miotto K. Medications for heavy drinking smokers: Singular and combined effects of varenicline and naltrexone. Alcoholism, Clinical and Experimental Research 2012; Vol. 35th Annual Scientific Meeting of the Research Society on Alcoholism (RSA) San Francisco, CA. 23 ‐ 27 June:366A. []

Additional references

Benowitz 1999
    1. Benowitz NL. Nicotine addiction. Primary Care 1999;26(3):611‐31. - PubMed
Benowitz 2010
    1. Benowitz NL. Nicotine addiction. New England Journal of Medicine 2010;362(24):2295‐303. - PMC - PubMed
Biala 2005
    1. Biała G, Budzyńska B, Kruk M. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine‐induced antinociception in mice. Pharmacological Reports 2005;57(6):755‐60. - PubMed
Blum 1995
    1. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE. Dopamine D2 receptor gene variants: association and linkage studies in impulsive‐addictive‐compulsive behaviour. Pharmacogenetics 1995;5(3):121‐41. - PubMed
Brandon 2012
    1. Brandon TH, Drobes DJ, Unrod M, Heckman BW, Oliver JA, Roetzheim RC, et al. Varenicline effects on craving, cue reactivity, and smoking reward. Psychopharmacology (Berl) 2011;218(2):391‐403. - PMC - PubMed
Cahill 2012
    1. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD006103.pub6] - DOI - PubMed
Corrigall 1991
    1. Corrigall WA, Coen KM. Opiate antagonists reduce cocaine but not nicotine self‐administration. Psychopharmacology (Berl) 1991;104(2):167‐70. - PubMed
CSAT 2009
    1. Center for Substance Abuse Treatment. Chapter 4: Oral naltrexone. Incorporating alcohol pharmacotherapies into medical practice www.ncbi.nlm.nih.gov/books/NBK64042/. Rockville, MD: Substance Abuse and Mental Health Services Administration (US), 2009. - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses (Section 9.2.2.3 Warning: OR and RR are not the same). In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011.
Farley 2012
    1. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD006219.pub3] - DOI - PubMed
Fiore 2008
    1. Fiore M, Tobacco Use, Dependence Panel. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: U.S. Department of Health and Human Services, 2008.
Goodrich 1990
    1. Goodrich PM. Naloxone hydrochloride: a review. American Association of Nurse Anaesthetists Journal 1990;58(1):14‐6. - PubMed
Gourlay 2008
    1. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD000058.pub2] - DOI
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011.
Hughes 2007
    1. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD000031.pub3] - DOI - PubMed
Isola 2002
    1. Isola R, Zhang H, Duchemin AM, Tejwani GA, Neff NH, Hadjiconstantinou M. Met‐enkephalin and preproenkephalin mRNA changes in the striatum of the nicotine abstinence mouse. Neuroscience Letters 2002;325(1):67‐71. - PubMed
Malin 1993
    1. Malin DH, Lake JR, Carter VA, Cunningham JS, Wilson OB. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 1993;112(2‐3):339‐42. - PubMed
Malin 1996
    1. Malin DH, Lake JR, Payne MC, Short PE, Carter VA, Cunningham JS, et al. Nicotine alleviation of nicotine abstinence syndrome is naloxone‐reversible. Pharmacology, Biochemistry and Behavior 1996;53(1):81‐5. - PubMed
Meyer 1984
    1. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, dose‐proportionality, and pharmacokinetics of naltrexone after oral administration. Journal of Clinical Psychiatry 1984;45(9 Pt 2):15‐9. - PubMed
Mills 2012
    1. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high‐dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta‐analysis. Annals of Medicine 2012;44(6):588‐97. - PubMed
Pomerleau 1983
    1. Pomerleau OF, Fertig JB, Seyler LE, Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology 1983;82:530‐7. - PubMed
SAMHSA 2013
    1. Substance Abuse and Mental Health Services Agency. About buprenorphine therapy. http://buprenorphine.samhsa.gov/about.html (accessed 15th February 2013).
Shiffman 2000
    1. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 2000;148:33‐40. - PubMed
Stead 2012
    1. Stead LF, Perera R, Bullen C, Mant D, Hartmann‐Boyce J, Cahill K, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD000146.pub4] - DOI - PubMed
USDHHS 2010
    1. US Department of Health and Human Services. A report of the Surgeon General: how tobacco smoke causes disease: the biology and behavioral basis for smoking‐attributable disease. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010.
Volpicelli 1992
    1. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 1992;49(11):49. - PubMed

References to other published versions of this review

David 2001
    1. David S, Lancaster T, Stead LF. Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD003086] - DOI - PubMed
David 2003
    1. David S, Lancaster T, Stead LF. Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD003086.pub2] - DOI - PubMed
David 2006
    1. David S, Lancaster T, Stead LF, Evans AE, Cahill K. Opioid antagonists for smoking cessation. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003086.pub2] - DOI - PubMed

Publication types

MeSH terms